Iterum Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Iterum Therapeutics's estimated annual revenue is currently $4.8M per year.
- Iterum Therapeutics's estimated revenue per employee is $209,739
- Iterum Therapeutics's total funding is $203.4M.
Employee Data
- Iterum Therapeutics has 23 Employees.
- Iterum Therapeutics grew their employee count by 5% last year.
Iterum Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | Head Human Resources, Global | Reveal Email/Phone |
4 | SVP and Head Clinical Development | Reveal Email/Phone |
5 | SVP Technical Operations | Reveal Email/Phone |
6 | SVP, Legal Affairs | Reveal Email/Phone |
7 | VP, Head Commercial Planning & Business Development | Reveal Email/Phone |
8 | Senior Director, Clinical Development Operations | Reveal Email/Phone |
9 | Chief Medical Officer | Reveal Email/Phone |
10 | Associate Director, External Manufacturing | Reveal Email/Phone |
Iterum Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $28.7M | 143 | 7% | N/A | N/A |
#2 | $4.8M | 23 | 5% | $203.4M | N/A |
#3 | $26.7M | 133 | N/A | N/A | N/A |
#4 | $14.9M | 74 | 7% | N/A | N/A |
#5 | $2.4M | 12 | -20% | N/A | N/A |
#6 | $28.9M | 144 | 1% | N/A | N/A |
#7 | $16.7M | 83 | 5% | N/A | N/A |
#8 | $17.7M | 88 | 4% | N/A | N/A |
#9 | $49.4M | 246 | 4% | N/A | N/A |
#10 | $106.1M | 528 | 1% | N/A | N/A |
What Is Iterum Therapeutics?
Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum's first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. For more information on Iterum Therapeutics please visit www.iterumtx.com.
keywords:N/A
$203.4M
Total Funding
23
Number of Employees
$4.8M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Iterum Therapeutics News
Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results. Published: Mar 28, 2022. --Registration Trial for uUTI Planned in Second...
Iterum Therapeutics press release (NASDAQ:ITRM): Q4 GAAP EPS of -$0.02 beats by $0.02. Cash, cash equivalents and short-term investments of...
Here's what investors need to know before the announcement. Analysts estimate that Iterum Therapeutics will report an earnings per share (EPS)...
Iterum knew its odds were slim as it awaited an FDA ruling on a key urinary tract infection drug with its bank account running low. The FDA, however, wasn’t impressed, and Iterum’s days look numbered. The FDA has sent the tiny biotech a complete response letter for the antibiot ...
Other Companies in Dublin
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.3M | 23 | 10% | N/A |
#2 | $2.3M | 23 | N/A | N/A |
#3 | $3.3M | 23 | 10% | N/A |
#4 | $4M | 23 | 0% | N/A |
#5 | $3.9M | 23 | 5% | N/A |